Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity.

"Declarations Conflicts of interestPM is a Medical Research Council (MRC)-GlaxoSmithKline EMINENT clinical training fellow with project funding outside of the submitted work; PM reports consultancy fees from SOBI, Abbvie, UCB, EUSA Pharma, Boehringer Ingelheim and Lilly outside of the submitted work. IOR reports funding for an investigator initiated clinical trial from Genentech on behalf of the TRAIL network in addition to participation in advisory boards of Boehringer Ingelheim and Genentech/Roche. MS reports grants outside of this project from Apollo Therapeutics, the UCL Technology Fund, the Wellcome Trust, MRC, Rosetrees Trust and NIHR. Others (personal or to institution) from Abbott, Biomerieux, Biotest, Deltex Medical, Enlivex, Fresenius, Hemotune, NewB, Paion, Radiometer, Roche Diagnostics, Safeguard Biosystems and Spiden outside of this project. Ethical declarationsNot applicable. Conflicts of interest PM is a Medical Research Council (MRC)-GlaxoSmithKline EMINENT clinical training fellow with project funding outside of the submitted work; PM reports consultancy fees from SOBI, Abbvie, UCB, EUSA Pharma, Boehringer Ingelheim and Lilly outside of the submitted work. IOR reports funding for an investigator initiated clinical trial from Genentech on behalf of the TRAIL network in addition to participation in advisory boards of Boehringer Ingelheim and Genentech/Roche. MS reports grants outside of this project from Apollo Therapeutics, the UCL Technology Fund, the Wellcome Trust, MRC, Rosetrees Trust and NIHR. Others (personal or to institution) from Abbott, Biomerieux, Biotest, Deltex Medical, Enlivex, Fresenius, Hemotune, NewB, Paion, Radiometer, Roche Diagnostics, Safeguard Biosystems and Spiden outside of this project."

"Declarations: Conflicts of interestPM is a Medical Research Council (MRC)-GlaxoSmithKline EMINENT clinical training fellow with project funding outside of the submitted work; PM reports consultancy fees from SOBI, Abbvie, UCB, EUSA Pharma, Boehringer Ingelheim and Lilly outside of the submitted work. IOR reports funding for an investigator initiated clinical trial from Genentech on behalf of the TRAIL network in addition to participation in advisory boards of Boehringer Ingelheim and Genentech/Roche. MS reports grants outside of this project from Apollo Therapeutics, the UCL Technology Fund, the Wellcome Trust, MRC, Rosetrees Trust and NIHR. Others (personal or to institution) from Abbott, Biomerieux, Biotest, Deltex Medical, Enlivex, Fresenius, Hemotune, NewB, Paion, Radiometer, Roche Diagnostics, Safeguard Biosystems and Spiden outside of this project.: Ethical declarationsNot applicable."